Ariana Pelosci

T-DXd plus pertuzumab improved progression-free survival vs THP regardless of prior therapy, hormone receptor status, or PIK3CA mutations.

A 1-time dose of arlo-cel demonstrated safety and efficacy in patients with relapsed or refractory multiple myeloma that was previously treated.

Patients with intermediate- or high-risk MDS experienced a higher modified overall response rate with the venetoclax/azacitidine vs placebo/azacitidine.

Survey results show patients may overestimate dermatologic AEs from anti-cancer therapies, raising concerns for treatment adherence.

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says Cathy Bradley, PhD.

Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with cisplatin/radiotherapy in LA-SCCHN.

Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

The phase 2 FDZL-001 trial showed high overall survival and progression-free survival rates with camrelizumab plus Nab-POF in patients with gastric/GEJ cancer.

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.

A nurse practitioner discusses the importance of compassionate end-of-life care discussions.

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary cholangitis, respectively.

Pain management specialists were rarely consulted for cancer-related pain, a recent study showed.

Pelvic transposition may improve quality of life and preserve fertility in patients with gynecologic cancer undergoing pelvic radiation.

Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine therapy.

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

SON-080, a novel drug, may reduce chemotherapy-induced peripheral neuropathy in patients previously treated with chemotherapy.

Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.

A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Tolerable anti-tumor activity was demonstrated in patients with HER2-overexpressing non–small cell lung cancer who were treated with trastuzumab deruxtecan at 2 dose levels.

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

Nurse coordinators should aim to transmit information to both the patient and caregiver during outpatient CAR T-cell treatment process.

A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.

Differences in gut microbiome signatures may lead to more accurate treatments and diagnoses for patients with colorectal cancer.

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.